Fingerprint

Dive into the research topics of 'Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial'. Together they form a unique fingerprint.

Medicine & Life Sciences